Therapy Type: Small Molecule (timeline)
Target Type: Unknown
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Phase 1)
Pfizer lists PF-05251749 in its November 2016 pipeline as being a Phase 1 compound for Alzheimer's disease, but has not disclosed its mechanism of action. No preclinical information is available in the public domain, but trial details suggest an agent that affects APP metabolism. This drug is given as an oral suspension.
Between July 2015 and July 2016, Pfizer conducted a first-in-human, single- and multiple-ascending-dose trial of PF-06751979 in 55 healthy people in California. Doses ranged from 3 to 160 mg; treatment duration was up to two weeks. Primary outcome measures included a wide range of safety measures; secondary outcomes included plasma pharmacokinetics, as well as quantification of various CSF Aβ fragments at baseline and at two weeks.
In June 2016, a second trial started enrolling 54 elderly volunteers to evaluate single and multiple ascending doses ranging from 200 to 700 mg against placebo. Outcomes include numerous safety and pharmacokinetic and -dynamic measures, as well as measurement of these Aβ fragments: Aβ1-40, Aβ1-42, Aβ total, Aβx-40, Aβx 42, sAPPα, sAPPβ. This trial is taking place in Belgium.
For all trials on this compound, see clinicaltrials.gov.
No Available Further Reading